Decred (DCR) is trading at $17.46, down 2.74% over 24 hours. The price is about 46% of the way from the $16.79 low to the $18.26 high, putting it slightly below the day’s $17.525 midpoint rather than near either extreme.

The hourly moving averages show a mostly bearish short-term configuration: DCR is above the 8-hour SMA at $17.38, but below the 13-, 21-, 55-, and 144-hour averages, which range from $17.59 to $18.20. The longer averages are progressively higher, so the price would need to recover above several levels to reverse this signal; the 8-hour average is a limited near-term positive.

Momentum readings are weak but not deeply oversold. The 1-hour RSI of 44 and 7-day RSI of 46 are both below 50, consistent with subdued momentum, while neither reading alone signals an extreme condition.

Returns across the supplied periods reinforce the short-term weakness: DCR is down 4.31% over seven days and 5.15% over 14 days. The 30-day change is slightly positive at 0.69%, however, which tempers the negative shorter-term picture and suggests the recent decline has not erased the modest monthly gain.

The supplied 24-hour volume is 870,637, and volume-to-market-cap is 0.28%. These figures provide activity context, but without a comparison period or further volume data they do not independently establish whether selling pressure is strengthening or easing.

DCR remains about 92.9% below its $247.35 all-time high from April 16, 2021. That large historical decline describes the distance from the recorded peak, but the supplied data do not show a current trend reversal or make the old high a useful near-term price target.

The evidence is mixed, but the short-term balance leans bearish: the daily and multi-day price changes are negative, both RSI readings are below 50, and price sits beneath four of the five hourly moving averages. Against that, DCR remains marginally positive over 30 days, is above its 8-hour average, and is not at the bottom of its daily range.

Overall, the rating is Hold. The bearish short-term momentum argues against a Buy, while the modest positive 30-day return and price above the 8-hour average do not support a stronger Sell; the key evidence is the combination of near-term weakness with limited, conflicting signs of resilience.